Methionine adenosyltransferase (MAT) has been partially purified from rat lenses using a combination of ammonium sulfate fractionation and hydrophobic chromatography on phenyl Sepharose columns. The partially purified enzyme resembles purified Type II MAT from non-hepatic tissues. The Km for methionine is 3.0 microM, and the Km for ATP is 80 microM. The enzyme is activated by potassium ions (25-50 mM), and inhibited by higher concentrations of potassium. A divalent cation (magnesium or manganese) is essential for activity. The Vmax with magnesium is about five times higher than with manganese, but the optimal manganese concentration is around 2.0 mM, compared with 10-20 mM for magnesium. The enzyme is active over a broad pH range, with optimal activity between pH 7.0 and 8.0. The enzyme is inhibited by all three of its products, phosphate, pyrophosphate, and S-adenosylmethionine. Individually phosphate and pyrophosphate are weak inhibitors, but in combination they show a marked synergistic inhibitory effect. Tripolyphosphate is also an effective inhibitor. The inhibition of the enzyme by the cataractogenic agent, dimethylsulfoxide, further confirmed the similarity to Type II MAT.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0014-4835(86)90077-1DOI Listing

Publication Analysis

Top Keywords

methionine adenosyltransferase
8
partially purified
8
type mat
8
phosphate pyrophosphate
8
enzyme
5
purification properties
4
properties rat
4
rat lens
4
lens methionine
4
adenosyltransferase methionine
4

Similar Publications

Homozygous MTAP deletion occurs in ~15% of cancers, making them vulnerable to decreases in the concentration of S-adenosylmethionine (SAM). AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 A (MAT2A), the enzyme primarily responsible for the synthesis of SAM. We report results from the first-in-human, phase 1 trial of AG-270/S095033 as monotherapy in patients with advanced malignancies (ClinicalTrials.

View Article and Find Full Text PDF

Discovery of 2(1)-Quinoxalinone Derivatives as Potent and Selective MAT2A Inhibitors for the Treatment of MTAP-Deficient Cancers.

J Med Chem

January 2025

Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.

Article Synopsis
  • MAT2A is a promising target for cancer treatment, especially in tumors with MTAP gene deletion, but there are challenges in ensuring the selectivity of MAT2A inhibitors for these specific cancers.
  • Recent research led to the identification of new MAT2A inhibitors with a unique 2(1)-quinoxalinone structure that effectively inhibit MAT2A and selectively target MTAP-deficient cancer cells.
  • One of the novel compounds demonstrated strong pharmacokinetic properties and showed enhanced anticancer effects in models with MTAP-deficient tumors, highlighting potential advancements in drug development for these cancer types.
View Article and Find Full Text PDF

Genome-wide association analysis of key genes for feed efficiency in Qingyuan Partridge chickens.

Poult Sci

December 2024

Guangdong Provincial Key Laboratory of Animal Molecular Design and Precise Breeding, School of Life Science and Engineering, Foshan University, Foshan 528225, China; Guangdong Tinoo's Food Co., Ltd., Qingyuan, Guangdong 511500, China. Electronic address:

Qingyuan Partridge chickens represent a notable breed of high-quality, slow-growing chickens. The cost of feed constitutes 65-70 % of the total breeding expense for Qingyuan Partridge chickens. Enhancing feed utilization efficiency and reducing feed consumption are crucial for the advancement of Qingyuan Partridge chickens and the broader poultry industry.

View Article and Find Full Text PDF

Rationale: The high clinical heterogeneity of hypermethioninemia caused by MAT1A gene defects has resulted in a paucity of studies examining the association between clinical phenotypes, biochemical characteristics, and gene mutations in this patient group. Furthermore, the indications for therapeutic interventions in patients remain unclear. The objective of this study is to provide a foundation for clinical diagnosis, genetic counseling, and follow-up management of hypermethioninemia caused by MAT1A gene defects.

View Article and Find Full Text PDF

Background: In Europe, canine leishmaniasis is commonly caused by Leishmania infantum. Allopurinol is the main drug for long-term management of the disease, and clinical relapses of L. infantum infection treated with this drug are described.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!